Short Interest in IPSEN (OTCMKTS:IPSEY) Expands By 87.4%

IPSEN (OTCMKTS:IPSEY) was the target of a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 268 shares, a growth of 87.4% from the June 15th total of 143 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily trading volume, of 1,589 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

A number of research firms have recently commented on IPSEY. Zacks Research raised IPSEN to a “hold” rating in a research note on Friday, May 29th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, HC Wainwright restated a “buy” rating on shares of IPSEN in a research note on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, IPSEN presently has an average rating of “Hold”.

IPSEN Stock Performance

IPSEY remained flat at $44.07 during trading on Thursday. The company’s stock had a trading volume of 383 shares, compared to its average volume of 993. The business’s 50-day moving average is $46.77 and its 200 day moving average is $44.75. IPSEN has a 1-year low of $30.05 and a 1-year high of $51.10.

IPSEN Company Profile

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).